Structural analyses

The avail­ab­le anony­mi­sed pre­scrib­ing data can be used to deter­mi­ne the mar­ket and con­cen­tra­ti­ons in any way, wit­hin the cons­traints of data pro­tec­tion law. Your needs as well as con­cep­tu­al sug­ges­ti­ons by phar­mafakt can be taken into account fle­xi­b­ly when crea­ting cate­go­ries of poten­ti­al. Rele­vant infor­ma­ti­on is com­pres­sed into a tailo­red aggre­ga­ti­on level. This means your infor­ma­ti­on requi­re­ments are met in a high­ly indi­vi­du­al way. The avail­ab­le infor­ma­ti­on can be used to exami­ne the value of your exis­ting tar­get group clus­ters and, if need be, to high­light scope for opti­mi­sa­ti­on. Final­ly, the inter­sec­tion bet­ween the cate­go­ries of poten­ti­al crea­ted using the pre­scrib­ing infor­ma­ti­on and the tar­get group fea­tures you pro­vi­de can be used to make exact and uner­ring value state­ments about the qua­li­ty of the respec­tive tar­get group clus­ters.

ST_Konzentrationskurve_Wirkstoff_vs_Markt_UK

Click to enlar­ge gra­phic!

ST_Overlap_Analyse_bei_API_3_ausgewaehlte_Wirkstoffe_UK

Click to enlar­ge gra­phic!

Our opti­ons enab­le us to exami­ne the market- and product-concentrations for tailo­red pre­scrib­ing clus­ters. We pro­vi­de you with exact and uner­ring value state­ments about your exis­ting tar­get groups with the opti­on of opti­mi­zing the­se with signi­fi­cant­ly impro­ved tar­get group effec­tiveness.

Our custo­mer advi­sers will be hap­py to pro­vi­de more detail­ed infor­ma­ti­on about our ana­ly­sis opti­ons.